Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 3/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23719 | 0.89 | ENPP2 (0.65) | ENPP2NPC1RAB9ATDP1MAOB | |
| SCHEMBL22874 | 0.89 | ENPP2 (0.70) | ENPP2RAB9AMAOBAPP | |
| SCHEMBL12420271 | 0.89 | ENPP2 (0.54) | ENPP2MAOBAPP | |
| SCHEMBL15332207 | 0.88 | MAOB (0.67) | ENPP2NPC1RAB9ATDP1MAOB | |
| SCHEMBL29952469 | 0.88 | MAOB (0.62) | ENPP2NPC1RAB9AMAOBAPP | |
| SCHEMBL17236537 | 0.87 | APP (0.53) | ENPP2RAB9ATDP1MAOBAPP | |
| SCHEMBL2560615 | 0.86 | MAOB (0.66) | ENPP2RAB9AMAOBAPP | |
| SCHEMBL16687440 | 0.86 | ENPP2 (0.56) | ENPP2MAOBAPP | |
| SCHEMBL15331009 | 0.86 | ENPP2 (0.74) | ENPP2NPC1RAB9AMAOBNLRP3 | |
| SCHEMBL22315 | 0.85 | CYP4F2 (0.58) | ENPP2RAB9AMAOBSMPD1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3317278-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3317278-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9902703-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2017003724-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885NPC1 1529/4885RAB9A 1191/4885 |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | ENPP2 1718/4885NPC1 725/4885RAB9A 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.